← All trials
NCT05364580
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 6, 2023
- Primary completion
- Jun 20, 2023
- Completion date
- Oct 6, 2023
- First posted
- May 6, 2022
- Last posted
- Nov 18, 2023
- Enrollment
- 269
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Protox Inc.Lead sponsor
- Chung-Ang UniversityOfficial
- Konkuk UniversityOfficial
- Kyung Hee UniversityOfficial
- Pusan National UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.